Author

Cynthia Sandoval Rubenstein

Observed names: C.S. Rubenstein, Cynthia Sandoval

Observed institution: Eli Lilly (United States)

OpenAlex ID: A5113195982

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

2024 · Kevin Kalinsky, Giampaolo Bianchini, et al. · Journal of Clinical Oncology · 98

Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

2024 · Sherene Loi, Stephen R. D. Johnston, et al. · Journal of Clinical Oncology · 40

Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

2024 · Nicholas Turner, Jorge Reis-Filho, et al. · Cancer Research · 13

3MO Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE

2024 · C. Desmedt, N. Turner, et al. · ESMO Open · 10

240MO Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)

2023 · M.P. Goetz, N. Turner, et al. · Annals of Oncology · 4

Abstract PS06-01: Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer

2024 · Sherene Loi, Stephen Johnston, et al. · Cancer Research · 3

Abstract P1-01-26: Genomic profiling of ctDNA & assoc. w/ efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy

2025 · Seth A. Wander, Kevin Kalinsky, et al. · Clinical Cancer Research

6MO Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients

2025 · S. Wander, E.P. Hamilton, et al. · ESMO Open

P002: Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial

2025 · C.S. Rubenstein, N. Turner, et al. · The Breast

Works count: 9

Citation count: 168

H-index: 4

I10-index: 4